Actively Recruiting
A Phase 2a Study of Riluzole to Improve Brain-Derived Neurotrophic Factor Levels and Cognitive Function in Adults With Cancer-Related Cognitive Impairment
Led by University of California, Irvine · Updated on 2026-07-14
75
Participants Needed
1
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating riluzole therapy in a phase 2a randomized, double-blinded, placebo-controlled pilot trial to study its effect on brain-derived neurotrophic factor BDNF levels in cancer survivors or patients who have undergone whole brain radiation for tumors and experience cancer-related cognitive impairment. The trial aims to understand how riluzole impacts cognitive function in these patients. This study is led by the University of California, Irvine. Participants are randomly assigned to take either 50 mg of riluzole or a matching placebo capsule twice daily for 8 weeks. The trial includes two groups one receiving riluzole and the other receiving placebo. Both treatments are given orally. The study lasts 8 weeks, during which the effects on circulating BDNF levels and cognitive function are monitored. Throughout the study, participants will be assessed for changes in BDNF levels and cognitive function using questionnaires and computerized tests. Researchers will measure cognitive function scores using FACT-Cog and CANTAB tools at the 8-week mark. Safety and tolerability are monitored, and participants are expected to complete questionnaires and assessments in English, Chinese, Korean, Vietnamese, or Spanish. The total participation time is about 8 weeks, with regular follow-ups during this period.
CONDITIONS
Brief Title
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
Research Team
C
Chao Family Comprehensive Cancer Center University of California, Irvine
U
University of California Irvine Medical
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here